Newspapers and networks are wary of exposing their staff members to the president and his aides, saying they do not have assurance that basic precautions will be taken to protect reporters’ health.
More
President Donald Trump has returned to the campaign trail less than two weeks after testing positive for coronavirus.v
More
Multilateral responses to the global security challenges in the time of the COVID-19 pandemic, and the OSCE's comprehensive engagement are the focus of the two-day 2020 OSCE Asian Conference, virtually hosted by the Republic of Korea, in close co-operation with Slovakia, the 2020 OSCE Asian Partners for Co-operation Group Chair.
More
The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection
More
Today, the Commission announces the first provisional results of the implementation of the Coronavirus Response Investment Initiative (CRII) and Coronavirus Response Investment Initiative Plus (CRII+).
More
This morning, the President of the European Commission, Ursula von der Leyen, addressed the opening session of this year's edition of the European Week of Regions and Cities via videoconference.
More
One of the challenges of measuring the economy through the pandemic has been estimating the contribution of the public sector, when the relationship between public spending and outputs – for example classes taught or operations conducted – is very different from pre-COVID-19 times. Katherine Mills talks about how we’ve approached the issue.
More
A challenge faced by the ONS during the pandemic is the inability to conduct face-to-face household interviews, having to rely on telephone surveys instead. So we’ve been exploring how this might have affected responses to our Labour Force Survey on which the key UK employment data are based. Jonathan Athow explains what we have
More
Six new projects worth a total of £2 million will give a much-needed boost in support for research investigating the impact of the COVID-19 pandemic on mental health.
More
In a continuing effort to provide the facts about ID NOW to support public health interests, Abbott (NYSE: ABT) is sharing new interim clinical data results on its ID NOW COVID-19 rapid test. The results confirm the data submitted to the U.S. Food and Drug Administration (FDA) in March for Emergency Use Authorization (EUA) and
More